Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. pain and inflammation
Show results for

Refine by

Pain And Inflammation Articles & Analysis

25 news found

What to Expect for an Epidural Injection

What to Expect for an Epidural Injection

Epidural steroid injections have been a key feature in rehabilitation regimens for many decades, and they continue to grow as a popular means of pain relief. Most professionals agree that epidural steroid injections continue to be an effective mechanism in alleviating nerve pain and inflammation. ...

ByMilestone Scientific, Inc.


SANUWAVE Health Announces Issuance of Eleven New Patents Bringing the Company`s Total Number of Active Patents and Patent Applications to 150

SANUWAVE Health Announces Issuance of Eleven New Patents Bringing the Company`s Total Number of Active Patents and Patent Applications to 150

SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for shockwave systems in the non-medical field, announced today the patent activity for the full year 2020 and the first quarter of ...

BySanuwave and Sanuwave Health, Inc.


Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Food and Drug Administration (FDA) approved medicine for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS, a twice-a-day corticosteroid for the treatment of post-operative inflammation and pain following ocular ...

ByKala Pharmaceuticals, Inc.


Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD

Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD

PPP004 was developed to help manage pain and itch in patients with EB and promote wound healing. PPP004 containing CBD only has been granted ODD by both the U.S. ...

ByTetra Bio-Pharma


Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

About Panag Pharma Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the ...

ByTetra Bio-Pharma


SANUWAVE Health Announces Patent Activity from March 2021 to March 2022

SANUWAVE Health Announces Patent Activity from March 2021 to March 2022

The patent portfolio covers specific constructions for ultrasound systems, combination systems, drug delivery, and methods to apply such ultrasound technology for different medical afflictions such as wounds, pain, inflammation, etc. This robust patent portfolio includes a total of 47 active patents and patent applications, with 10 pending patent applications, ...

BySanuwave and Sanuwave Health, Inc.


HTI announces Dr. Doug Kawahara as Senior Advisor for AI/ML Drug Discovery

HTI announces Dr. Doug Kawahara as Senior Advisor for AI/ML Drug Discovery

(fka Corgentech, South San Francisco, CA), a developer of drugs for treating pain and inflammation, and Director, Corporate Development, at GeneTrol Biotherapeutics (Oakland, CA), a developer of therapeutic proteins for the treatment of cancer, viral infections and autoimmune diseases. ...

ByHealth Technology Innovations, Inc.


Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD

Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD

Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing ...

ByTetra Bio-Pharma


Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna

Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna

Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing ...

ByTetra Bio-Pharma


Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

If left untreated, MGD can present serious consequences, including ocular surface damage, changes in tear film stability, inflammation, pain, chronic dry eye, and other symptoms that can greatly impair a person’s daily life and vision. ...

BySight Sciences, Inc.


Tetra Bio-Pharma Announces Closing of $2.1 Million Marketed Public Offering of Units

Tetra Bio-Pharma Announces Closing of $2.1 Million Marketed Public Offering of Units

Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing ...

ByTetra Bio-Pharma


Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™

Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™

The REBORN©1 trial is a head-to-head, open-label, crossover phase 2 study against oral opioids in the management of short and frequent episodes of incapacitating pain (breakthrough pain) in patients with cancer. The REBORN©1 study protocol is assessing the safety and preliminary efficacy of QIXLEEF™ in onset of pain relief and on ...

ByTetra Bio-Pharma


QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols

QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols

Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing ...

ByTetra Bio-Pharma


Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™

Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™

The drug will be first indicated in patients with cancer suffering of uncontrolled breakthrough pain (REBORN© trials) then in patients with advanced cancer with inadequately controlled pain (PLENITUDE© trials). QIXLEEF™, with its innovative and proprietary dosing data, provides fast acting relief from pain, offering patients a ...

ByTetra Bio-Pharma


U.S. Nationwide Commercial Availability of the VenSure Balloon Sinus Dilation System and Cube Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

U.S. Nationwide Commercial Availability of the VenSure Balloon Sinus Dilation System and Cube Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

Over time, the sinuses can become infected leading to inflammation and pain. Up to 60% of CRS patients may not experience significant improvements in their symptoms despite trying multiple over the counter and prescription medications. ...

ByIntersect ENT, Inc.


CBD For Beginners: Everything you should Know About Cannabidiol

CBD For Beginners: Everything you should Know About Cannabidiol

For anyone just now considering CBD, there are tons of questions you may have, and we’re here to help answer them. Those with chronic pain conditions, like joint inflammation or muscle pain, are likely to have heard its potential in helping reduce the severity of these issues. ...

ByMedcbdx


LayerBio CEO Presents OcuRing-K at OIS Anterior Innovation Showcase

LayerBio CEO Presents OcuRing-K at OIS Anterior Innovation Showcase

Ken Mandell, Founder and CEO of LayerBio, presented an update on the development of its novel OcuRing-K ketorolac implant for treatment of postoperative pain and inflammation with cataract surgery. To see video, please click ...

ByLayerBio, Inc


How Often should you Take CBD?

How Often should you Take CBD?

Here’s a quick CBD benefits list that captures why building up CBD in your system can be even better than just taking it occasionally. Helps reduce pain in your body. It’s not a narcotic and it can’t totally erase the sensory feeling of pain, however existing research shows that CBD can be successful in reducing pain and ...

ByMedcbdx


Feldan Therapeutics forms A Scientific Advisory Board and Expands Its Leadership Team

Feldan Therapeutics forms A Scientific Advisory Board and Expands Its Leadership Team

Gries has had exposure over a broad range of disease areas: oncology, inflammation and pain, the central nervous system, metabolism, cardio-renal syndrome, anti-infectives (including HIV and HCV), dermatology, ophthalmology, genito-urinary and gastroenterology. ...

ByFeldan Therapeutics


National Bladder Awareness Month: A Look at the Facts about Pelvic Radiation Cancer Survivors

National Bladder Awareness Month: A Look at the Facts about Pelvic Radiation Cancer Survivors

Lipella Pharmaceuticals promotes awareness of hemorrhagic cystitis, a chronic painful syndrome that can be acquired by cancer patients who have received pelvic radiation therapy. PITTSBURGH, November 12, 2020 – During this November, Bladder Health Awareness Month, we promote the awareness of a serious bladder health condition, hemorrhagic cystitis, which affects many cancer survivors who ...

ByLipella Pharmaceuticals Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT